As more than 30 clinical trials are currently investigating BETi treatments for solid and hematological malignancies (www.clinicaltrials.gov), we checked for a functional interaction between LOXL2 expression and BRD4 inhibition. This evidence concerns the gene LOXL2 and hematologic disorder.